Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell

MT Newswires Live12-18

Corvus Pharmaceuticals (CRVS) said Wednesday that interim results from a phase 1 trial of its experimental drug soquelitinib to treat patients with moderate to severe atopic dermatitis showed a favorable safety and efficacy profile.

The company said that patients receiving soquelitinib showed a 55.9% reduction in the Eczema Area and Severity Index score at 28 days compared to a 27% reduction in the placebo group.

It added that by day 58, the soquelitinib group continued to improve with a 69.1% mean Eczema Area and Severity Index reduction score, while the placebo group showed a 19.1% reduction.

The drug developer said no significant safety issues were observed during the study.

The company also said that Samlyn Capital, which holds warrants to purchase 3.6 million shares, has submitted exercise notices for all warrants before the June 30, 2025 expiration date to generate about $12.7 million in proceeds.

Shares were down over 33% in recent premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492185596?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492185596","market":"sh","top_or_hot":-1,"title":"Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Corvus Pharmaceuticals (CRVS) said Wednesday that interim results from a phase 1 trial of its experimental drug soquelitinib to treat patients with moderate to severe atopic dermatitis showed a favorable safety and efficacy profile.</p><p>The company said that patients receiving soquelitinib showed a 55.9% reduction in the Eczema Area and Severity Index score at 28 days compared to a 27% reduction in the placebo group.</p><p>It added that by day 58, the soquelitinib group continued to improve with a 69.1% mean Eczema Area and Severity Index reduction score, while the placebo group showed a 19.1% reduction.</p><p>The drug developer said no significant safety issues were observed during the study.</p><p>The company also said that Samlyn Capital, which holds warrants to purchase 3.6 million shares, has submitted exercise notices for all warrants before the June 30, 2025 expiration date to generate about $12.7 million in proceeds.</p><p>Shares were down over 33% in recent premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 21:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Corvus Pharmaceuticals (CRVS) said Wednesday that interim results from a phase 1 trial of its experimental drug soquelitinib to treat patients with moderate to severe atopic dermatitis showed a ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492185596","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492185596","pubTimestamp":1734528716,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Corvus Pharmaceuticals  said Wednesday that interim results from a phase 1 trial of its experimental drug soquelitinib to treat patients with moderate to severe atopic dermatitis showed a favorable safety and efficacy profile.The company said that patients receiving soquelitinib showed a 55.9% reduction in the Eczema Area and Severity Index score at 28 days compared to a 27% reduction in the placebo group.It added that by day 58, the soquelitinib group continued to improve with a 69.1% mean Eczema Area and Severity Index reduction score, while the placebo group showed a 19.1% reduction.The drug developer said no significant safety issues were observed during the study.The company also said that Samlyn Capital, which holds warrants to purchase 3.6 million shares, has submitted exercise notices for all warrants before the June 30, 2025 expiration date to generate about $12.7 million in proceeds.Shares were down over 33% in recent premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4568":"美国抗疫概念","CRVS":"Corvus Pharmaceuticals, Inc."},"translate_title":"Corvus Pharma表示，特应性皮炎研究的数据显示了良好的安全性；盘前股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVS":0.9},"content_text":"Corvus Pharmaceuticals (CRVS) said Wednesday that interim results from a phase 1 trial of its experimental drug soquelitinib to treat patients with moderate to severe atopic dermatitis showed a favorable safety and efficacy profile.The company said that patients receiving soquelitinib showed a 55.9% reduction in the Eczema Area and Severity Index score at 28 days compared to a 27% reduction in the placebo group.It added that by day 58, the soquelitinib group continued to improve with a 69.1% mean Eczema Area and Severity Index reduction score, while the placebo group showed a 19.1% reduction.The drug developer said no significant safety issues were observed during the study.The company also said that Samlyn Capital, which holds warrants to purchase 3.6 million shares, has submitted exercise notices for all warrants before the June 30, 2025 expiration date to generate about $12.7 million in proceeds.Shares were down over 33% in recent premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492185596"}